The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added to standard care in patients with moderate-to-severe lupus.

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

This autoimmune disease may impact your skin as well as your nails and hair. Learn what to look for to treat lupus more effectively.

Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement. The cutaneous lesions, which range from a malar rash to more indurated, ...

The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...

Please provide your email address to receive an email when new articles are posted on . Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s ...

--VIB7734 potently depletedblood andtissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases-- -- Treatment with VIB7734 resulted in ...

Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...